Disturbed iron metabolism in phagocytes as a driver of chronic inflammation – a model of MS progression?

B13

Over the course of multiple sclerosis there are different ways how MS lesions can evolve. While some lesions can resolve, persistent phagocyte activation is observed in chronic-active lesions. Currently, we do not understand which factors determine the fate of MS lesions. Here, we hypothesize that the balance between iron release and buffering is a key switch that determines whether an inflammatory CNS lesion will resolve or persists. In the proposed project we therefore plan to char-acterize the regulation of iron buffering in demyelinating lesions, define its importance for lesion fate and explore its potential as a therapeutic target. Our research questions are:

    1. What role plays the Fth1 expression in phagocytes for the resolution of demyelinating lesions?
    2. What functions does Fth1 have in demyelinating lesions?
    3. Does iron chelation have the potential to prevent chronic inflammation and progressive neurodegeneration?

Dynamic tracking of Fth1 expresssion in phagocytes

 

 

 

 

 

 

 

Principal Investigators:

Univ.-Prof. Dr. med. Mikael Simons
Institut für Neuronale Zellbiologie
TU München
msimons@gwdg.de

Univ.-Prof. Dr. med. Martin Kerschensteiner
Institut für Klinische Neuroimmunologie
München
martin.kerschensteiner@med.uni-muenchen.de

News

Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more
Wed, 20/01/2021
A new study on neurological manifestations of severe COVID-19 reveals nervous system immune deficiency
Patients suffering from COVID-19 can develop concomitant and long-term symptoms in their nervous system. The most common symptom in this context is the loss of the sense of smell and taste, while more severe symptoms such as stroke, cerebral seizures, or meningitis are possible. A team of scientists from the medical faculties at the Universities […]...more